Molecure S.A. Logo

Molecure S.A.

ISIN: PLONCTH00011 | Ticker: MOC | LEI: 2594003L11V38ZCVKZ09

About Molecure S.A.

Company Description

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.

Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.

Year founded

2012

Served area

Worldwide

Headquarters

Żwirki I Wigury 101, 02-089 Warszawa – Poland

Filings & Publications

2021

Report Q1 H1 Q3 FY
Consolidated Report pl
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

2020

Report Q1 H1 Q3 FY
Consolidated Report
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Shareholder information

Shares outstanding

14,060,000

IPO

April 1, 2018

Stock exchange(s)

Warsaw Stock Exchange

Contact Investor Relations department

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.